Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Barlogie

Showing results (71-80 of 359) with videos related to

Pageof 36
Sort By:
Leukemia|August 7, 2009
The molecular characterization and clinical management of multiple myeloma in the post-genome eraY Zhou, B Barlogie, J D Shaughnessy
Hematological Oncology|April 1, 1988
High dose melphalan for refractory myeloma--the M.D. Anderson experienceB Barlogie, K A Dicke, R Alexanian
Cancer|August 1, 1981
Metastasizing malignant juxtaovarian tumor with terminal hypercalcemia: a case reportR L Abbot, B Barlogie, W A Schmidt
Annals of Internal Medicine|April 1, 1989
High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myelomaB Barlogie, L Smallwood, T Smith, et al.
Experimental Cell Research|March 1, 1977
Synchronization of mouse L-P59 cells by centrifugal elutriation separationM L Meistrich, R E Meyn, B Barlogie
Current Treatment Options in Oncology|June 12, 2002
Waldenström's macroglobulinemiaK R Desikan, M V Dhodapkar, B Barlogie
Blood|March 1, 1989
Plasma cell myeloma--new biological insights and advances in therapyB Barlogie, J Epstein, P Selvanayagam, et al.
Die Medizinische Welt|September 27, 1974
[Cytokinetic effect of cytosine arabinoside in clinical tests]B Barlogie, T Büchner, U Asseburg, et al.
Blood|April 1, 1988
Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvementJ Epstein, B Barlogie, J Katzmann, et al.
Cancer Research|March 1, 1983
Selective protection by anguidine of normal versus transformed cells against 1-beta-D-arabinofuranosylcytosine and AdriamycinR Hromas, B Barlogie, D Swartzendruber, et al.
Pageof 36

Showing results (71-80 of 359) with videos related to

Sort By:
Pageof 36
Leukemia|August 7, 2009
The molecular characterization and clinical management of multiple myeloma in the post-genome eraY Zhou, B Barlogie, J D Shaughnessy
Hematological Oncology|April 1, 1988
High dose melphalan for refractory myeloma--the M.D. Anderson experienceB Barlogie, K A Dicke, R Alexanian
Cancer|August 1, 1981
Metastasizing malignant juxtaovarian tumor with terminal hypercalcemia: a case reportR L Abbot, B Barlogie, W A Schmidt
Annals of Internal Medicine|April 1, 1989
High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myelomaB Barlogie, L Smallwood, T Smith, et al.
Experimental Cell Research|March 1, 1977
Synchronization of mouse L-P59 cells by centrifugal elutriation separationM L Meistrich, R E Meyn, B Barlogie
Current Treatment Options in Oncology|June 12, 2002
Waldenström's macroglobulinemiaK R Desikan, M V Dhodapkar, B Barlogie
Blood|March 1, 1989
Plasma cell myeloma--new biological insights and advances in therapyB Barlogie, J Epstein, P Selvanayagam, et al.
Die Medizinische Welt|September 27, 1974
[Cytokinetic effect of cytosine arabinoside in clinical tests]B Barlogie, T Büchner, U Asseburg, et al.
Blood|April 1, 1988
Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvementJ Epstein, B Barlogie, J Katzmann, et al.
Cancer Research|March 1, 1983
Selective protection by anguidine of normal versus transformed cells against 1-beta-D-arabinofuranosylcytosine and AdriamycinR Hromas, B Barlogie, D Swartzendruber, et al.
Pageof 36